Stable Istotope Labelled Mepolizumab Biosimilar – Anti-IL5 mAb – Research Grade
Size | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Stable Istotope Labelled Mepolizumab Biosimilar - Anti-IL5 mAb - Research Grade |
---|---|
Source | CAS 196078-29-2 |
Species | Humanized |
Expression system | Mammalian cells |
Purity | >95% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue Ice |
Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Aliases /Synonyms | SB-240563 |
Reference | PX-TA1062-SIL |
Related Products | PX-P4558 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1-kappa |
Clonality | Monoclonal Antibody |
Source | CAS 196078-29-2 |
Format | Lyophilized |
Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
Isotopic Enrichment | 99% |
Stability | 1 year |
General information on Anti-IL5(Homo sapiens) (Mepolizumab) Monoclonal Antibody
Mepolizumab is a fully humanized recombinant IgG1 kappa monoclonal antibody directed against IL-5 produced in Chinese hamster ovary cells. (EGPA) and eosinophilia syndrome (HES). The pathogenesis of eosinophils is complex, but IL-5 is considered a key eosinophilic factor, involved in the differentiation, recruitment, activation and prolonged survival of eosinophils in peripheral tissues. Activated eosinophils further stimulate the inflammatory response, and also induce tissue damage and promote fibrosis, all of which contribute to the multifactorial symptoms of eosinophilic disease. Mepolizumab is used to treat severe asthma and is sold under the trade name Nucala.
Contact us
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.